Skip to main content
Equibles
RVMD logo

RVMD · Revolution Medicines, Inc. · Metrics

Track RVMD — free

Use RVMD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RVMD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$195.55 +13.40 (+7.36%)
Russell 1000 member Rebalance outlook locked
Market Cap
$39.04B
Shares
214.34M
Volume · Oct 20 2.73M Avg daily vol (3M) 1.97M

RVMD metrics

71 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$182.15
Market cap
$39.04B

Price action

20 metrics
Price change (1W)
-6.1%
Price change (30D)
-5.5%
Price change (3M)
+1.0%
Price change (6M)
+24.6%
Price change (YTD)
+128.7%
Price change (1Y)
+236.7%
Trailing year
Price change (5Y)
+562.8%
52-week high
$221.15
52-week low
$52.98
Change from 52-week high
-17.6%
Change from 52-week low
+243.8%
Annualized volatility
66.5%
Annualized volatility (3M)
40.1%
Beta
1.2
RSI (14D)
38.1
Price vs SMA 50
-10.1%
Price vs SMA 200
+19.7%
Avg volume (3M)
1.97M
Relative volume
1.0
Average dollar volume
$391.67M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
214.34M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
14.6
reciprocal yield 6.8%
FCF yield
-3.2%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-4.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$1.63B
Net income (TTM)
−$1.77B
Trailing 12 months
Diluted EPS (TTM)
$-8.86
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.00
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-8.17
EBITDA per diluted share (TTM)
$-8.12
Net income per diluted share (TTM)
$-8.84
Operating cash flow per diluted share (TTM)
$-6.13
Free cash flow per diluted share (TTM)
$-6.18
Capital expenditures per diluted share (TTM)
$0.05
R&D per diluted share (TTM)
$6.51
Stock compensation per diluted share (TTM)
$1.09
Book value per share
$8.28

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+11.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-67.8%
Return on assets
-40.9%
Debt / equity
—
Current ratio
11.4
EBITDA (TTM)
−$1.62B
Free cash flow (TTM)
−$1.23B
Quick ratio
11.4
Interest coverage
-27.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$3.94B
Latest balance sheet
Cash & equivalents
$815.43M
Total assets
$4.32B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$1.22B
Capital expenditures (TTM)
$9.10M
R&D (TTM)
$1.30B
SG&A (TTM)
—
Stock compensation (TTM)
$218.77M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
708
13F filer change QoQ
+182
Institutional ownership
107.0%
Conviction holders (share of 13F filers)
6.8%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+4.8%
Holder tenure
13.1
Price vs estimated holder cost
+151.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
13.8%

Short interest

3 metrics
Short interest
5.6%
Latest settlement · 4.7 days to cover
Days to cover
4.7d
Short-squeeze score
63 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$78.01M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1628171 CUSIP 76155X100 13F (30d) 96 filings 91 filers Visit website Investor relations